• linkedin
  • Increase Font
  • Sharebar

    OCTA system offers exquisite views

    New technology provides elegant look at retinal microvasculature without fluorescein dye

     

    Detailed imaging

    From the standpoint of the practitioners, the details of the retinal microvasculature provided by OCTA are “absolutely exquisite.”

    For example, in patients with diabetic retinopathy or retinal vein occlusion, the perfusion status of the macula is easily recognized as are areas of capillary dropout.

    “This ability is highly useful when managing these patients,” Dr. Esmaili said.

    Use of OCTA compared with fluorescein angiography is also managing to streamline ophthalmology practices, he pointed out.

    When performing fluorescein angiograms, the technicians are engaged with the patients for 20 to 30 minutes because of the need to access veins, take and process photographs, and transmit large data sets through a network

     

    More efficient offices

    “Using OCTA, we have noticed that our practice is running more efficiently. Patients are evaluated faster and we are staying on time in the clinic,” he noted.

    “OCTA is the next step in the evolution of OCT, and like all new technologies, there is a learning curve,” he said. “In the case of OCTA, it takes some practice for the ophthalmologist to appreciate normal versus abnormal findings and to identify artifacts. For our technicians and patients, it takes some practice to be able to acquire good images. Once a level of comfort is achieved, the benefits can be powerful.”

     

    Daniel D. Esmaili, MD

    E: [email protected]

    Dr. Esmaili is a speaker for OptoVue.

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';